Premium
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus
Author(s) -
Raschi Emanuel,
Poluzzi Elisabetta,
Koci Ariola,
Boriani Giuseppe,
De Ponti Fabrizio
Publication year - 2011
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2011.04065.x
Subject(s) - medicine , qt interval , amiodarone , adverse event reporting system , surrogate endpoint , long qt syndrome , adverse effect , cardiotoxicity , sudden cardiac death , cardiology , atrial fibrillation , intensive care medicine , chemotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom